Association of baseline continuous characteristics with PROs
| SLICC-DI | Age at enrolment | GC daily dose | Disease duration | SELENA-SLEDAI | |
| SF-36 PCS | Coef −0.04 p=0.000 | Coef −0.15 p=0.003 | Coef −0.05 p=0.004 | Coef −0.06 p=0.33 | Coef −0.01 p=0.30 |
| SF-36 MCS | Coef −0.01 p=0.1 | Coef −0.11 p=0.07 | Coef −0.01 p=0.35 | Coef −0.06 p=0.26 | Coef .002 p=0.88 |
| FACIT | Coef −0.04 p=0.000 | Coef −0.08 p=0.15 | Coef −0.03 p=0.16 | Coef 0.04 p=0.52 | Coef −0.01 p=0.61 |
| LIT | Coef 0.02 p=0.000 | Coef 0.067 p=0.58 | Coef 0.015 p=0.13 | Coef −0.03 p=0.29 | Coef 0.006 p=0.39 |
| HADS-A | Coef 0.06 p=0.03 | Coef 0.03 p=0.20 | Coef 0.099 p=0.14 | Coef 0.28 p=0.20 | Coef −0.04 p=0.45 |
| HADS-D | Coef 0.08 p=0.003 | Coef 0.04 p=0.10 | Coef 0.05 p=0.46 | Coef 0.25 p=0.29 | Coef −0.01 p=0.79 |
Bold values represent statistically significant values.
Coef, coefficient; FACIT, Functional Assessment of Chronic Illness Therapy; GC, glucocorticoids; HADS-A, Hospital Anxiety and Depression Scale for anxiety; HADS-D, Hospital Anxiety and Depression Scale for depression; LIT, Lupus Impact Tracker; PROs, Patient-Reported Outcomes; SELENA-SLEDAI, Safety of Estrogens in Lupus Erythematosus National Assessment-Systemic Lupus Activity Index; SF-36 MCS, Short Form 36 mental component summary; SF-36 PCS, Short Form 36 physical component summary; SLICC, Systemic Lupus International Collaborating Clinics.